20 likes | 150 Views
antiparasitic. immunomodulator. In vitro activity IC50: L.donovani amastigotes (in HMPC). CpG, others from literature, in clinical development, on market. Th1-type i.m./i.d./s.c. or topical Available for CL. Actives: test on panel of >5 CL isolates ( L.tropica , L.braziliensis ).
E N D
antiparasitic immunomodulator In vitro activity IC50: L.donovani amastigotes (in HMPC) CpG, others from literature, in clinical development, on market Th1-type i.m./i.d./s.c. or topical Available for CL Actives: test on panel of >5 CL isolates (L.tropica, L.braziliensis) In vivo efficacy: L.major infection in C57Bl/6 mice In vivo efficacy: L.major infection in C57Bl/6 mice + adjuvant? Choice based on: - Efficacy - Mode of action - Delivery - cost Combination therapy In vivo efficacy: L.major or L.Mexicana in C57Bl/6 mice Parameters: - Parasite load - Pathology - Type of T-cell response + adjuvant? In vivo efficacy: L.braziliensis in hamster model Added value of monkey model??